BIOATLA INC (BCAB)
US09077B1044 - Common Stock
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”)...
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS...
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical...
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024
BCAB stock results show that BioAtla met analyst estimates for earnings per share the second quarter of 2024.
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin...
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients...
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
BCAB stock results show that BioAtla beat analyst estimates for earnings per share the first quarter of 2024.
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioAtla (NASDAQ:BCAB) just reported results for the first quarter of 2024.BioAt...
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable...
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
BCAB stock results show that BioAtla beat analyst estimates for earnings per share the fourth quarter of 2023.
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioAtla (NASDAQ:BCAB) just reported results for the fourth quarter of 2023.BioA...
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical...
BioAtla CEO purchases 50K common shares (NASDAQ:BCAB)
BioAtla's CEO Jay Short purchases 50K shares at $2.1382/share, as the stock rises 14.8% on Thursday.
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses ...
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated...
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...